Cellectar Biosciences, Inc. Resources

News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • CLR 131
  • Clinical Trials
    • Overview
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Trial Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Trial Recruiting
    • Relapsed or Refractory Multiple Myeloma Clinical Trial Active, not recruiting
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar to Participate at Upcoming Institutional Investor Conferences

Mar 11, 2021

Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates

Mar 9, 2021

Cellectar to Participate at Upcoming Institutional Investor Conferences

Mar 5, 2021

Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update

Mar 2, 2021

Cellectar to Present at BIO CEO & Investor Digital Conference

Feb 10, 2021

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia

Jan 27, 2021

Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Jan 12, 2021

Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Dec 28, 2020

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Dec 23, 2020

Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement

Dec 22, 2020
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...26
© 2021 Cellectar Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Q&A